Morgan Stanley Maintains Equal-Weight on Moderna, Raises Price Target to $95

Benzinga Newsdesk www.benzinga.com Positive 56.9%

Neg 0% Neu 0% Pos 56.9%

Morgan Stanley analyst Terence Flynn maintains Moderna (NASDAQ:MRNA) with a Equal-Weight and raises the price target from $89 to $95.